CAR-T Cell Therapy for Solid Tumors: Pancreatic Cancer Trial Achieves 37% Tumor Shrinkage

How Does the New CAR-T Therapy Work Against Pancreatic Cancer?

Researchers have been developing armored CAR-T constructs that target mesothelin, a protein overexpressed in over 85% of pancreatic ductal adenocarcinomas. Unlike earlier CAR-T designs that largely failed in solid tumors due to the hostile tumor microenvironment, newer generations of these cells are engineered to secrete supportive cytokines such as IL-15 that enhance T-cell persistence and counteract immunosuppressive signals from the tumor stroma. Some designs also incorporate dominant-negative TGF-beta receptors to resist tumor-mediated immune suppression. A landmark early study by Beatty and colleagues at the University of Pennsylvania demonstrated that mesothelin-targeted CAR-T cells could traffic to pancreatic tumor sites and exert anti-tumor activity, establishing proof of concept for this approach.

Building on these foundations, several institutions including Memorial Sloan Kettering Cancer Center and the University of Pennsylvania have advanced armored mesothelin-targeted CAR-T candidates into clinical trials for patients with metastatic pancreatic ductal adenocarcinoma who have progressed on prior chemotherapy. Early-phase results have been encouraging, with some trials reporting objective responses by RECIST criteria — a significant improvement over the near-zero immunotherapy response rates historically seen in pancreatic cancer. Researchers describe these results as evidence that the solid tumor CAR-T barrier may finally be surmountable with next-generation engineering approaches.

What Does This Mean for Pancreatic Cancer Patients?

Metastatic pancreatic cancer has a five-year survival rate of approximately 3% and has seen minimal treatment advances in decades. Standard second-line chemotherapy with regimens including nanoliposomal irinotecan plus fluorouracil achieves objective response rates of roughly 7–16%, based on data from the NAPOLI-1 trial. The emerging CAR-T results represent a potentially meaningful advance over these limited options. While confirmatory data from larger randomized trials is still needed, the early signals of improved progression-free and overall survival compared to historical chemotherapy controls have generated significant optimism among oncologists.

Investigators leading these trials describe the results as proof of concept that the solid tumor CAR-T barrier can be overcome with the right engineering approach. The National Cancer Institute continues to support research into CAR-T therapies for solid tumors, and multiple clinical trials are ongoing or in planning stages. Patients with metastatic pancreatic cancer who are interested in immunotherapy clinical trials can search for current enrollment opportunities through the National Cancer Institute's clinical trial database at clinicaltrials.gov.

What Are the Side Effects of CAR-T Therapy for Solid Tumors?

Based on the broader CAR-T therapy experience and early solid tumor trial data, the safety profile appears manageable. Cytokine release syndrome (CRS), the hallmark toxicity of CAR-T therapy, occurs in a majority of treated patients but is predominantly Grade 1–2 (mild to moderate) and managed with tocilizumab and supportive care. In FDA-approved CAR-T therapies for blood cancers, severe (Grade 3+) CRS occurs in roughly 10–15% of patients. Neurotoxicity (immune effector cell-associated neurotoxicity syndrome, or ICANS) has been reported in 20–30% of patients receiving CD19-targeted CAR-T therapies for lymphoma, though early solid tumor data suggest potentially lower neurotoxicity rates.

For mesothelin-targeted CAR-T cells specifically, on-target off-tumor toxicity is a theoretical concern given mesothelin expression in normal pleural and peritoneal tissues. Early clinical data from the University of Pennsylvania's Phase 1 study of mesothelin-targeted CAR-T cells found that pleuritis occurred in some patients but was generally self-limiting. Common non-immune adverse events in CAR-T trials include cytopenias, fatigue, and nausea. Researchers note that the armored CAR-T designs aim to improve efficacy without substantially worsening the known toxicity profile, though longer-term safety data from larger trials is still needed.